Inventiva (NASDAQ:IVA) Shares Gap Down – What’s Next?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price gapped down prior to trading on Thursday . The stock had previously closed at $6.83, but opened at $6.38. Inventiva shares last traded at $6.29, with a volume of 217,467 shares traded.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the company. Guggenheim dropped their price target on Inventiva from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Tuesday, November 18th. Leerink Partners assumed coverage on Inventiva in a research report on Monday, January 12th. They issued an “outperform” rating and a $12.00 target price for the company. Wolfe Research raised Inventiva to a “strong-buy” rating in a research note on Thursday, November 6th. Wall Street Zen raised shares of Inventiva to a “hold” rating in a research note on Saturday, October 18th. Finally, Barclays assumed coverage on shares of Inventiva in a research note on Tuesday. They issued an “overweight” rating and a $18.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $16.22.

Inventiva Stock Performance

The business has a 50 day moving average price of $5.05 and a two-hundred day moving average price of $4.80.

Hedge Funds Weigh In On Inventiva

Large investors have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC increased its stake in shares of Inventiva by 54.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 16,558 shares of the company’s stock worth $50,000 after purchasing an additional 5,843 shares in the last quarter. Creative Planning bought a new stake in Inventiva during the second quarter valued at about $32,000. Millennium Management LLC purchased a new position in shares of Inventiva in the third quarter valued at about $649,000. NewEdge Advisors LLC bought a new position in shares of Inventiva in the third quarter worth about $116,000. Finally, UBS Group AG grew its position in shares of Inventiva by 28,881.6% during the fourth quarter. UBS Group AG now owns 2,643,702 shares of the company’s stock worth $12,293,000 after purchasing an additional 2,634,580 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.